tiprankstipranks
BioLineRX Ltd. (IL:BLRX)
TASE:BLRX
Israel Market
BLRX
Bioline Rx
RESEARCH TOOLSreports

Bioline Rx (BLRX) Ratios

2 Followers

Bioline Rx Ratios

IL:BLRX's free cash flow for Q4 2025 was $0.47. For the 2025 fiscal year, IL:BLRX's free cash flow was decreased by $ and operating cash flow was $-17.45. See a summary of the company’s cash flow.
Ratios
TTM
Dec 25Mar 25Dec 23Dec 22
Liquidity Ratios
Current Ratio
 1.95 1.95 1.76 1.10 4.87
Quick Ratio
 1.78 1.78 1.56 1.06 4.85
Cash Ratio
 0.27 0.27 0.68 0.10 0.99
Solvency Ratio
 -0.04 -0.04 -0.20 -1.17 -0.79
Operating Cash Flow Ratio
 -0.68 -0.72 -2.85 -0.53 -2.46
Short-Term Operating Cash Flow Coverage
 -1.75 -1.85 -9.80 -7.19 -17.02
Net Current Asset Value
$ 6.12M$ 6.12M$ 1.66M$ -3.52M$ 26.46M
Leverage Ratios
Debt-to-Assets Ratio
 0.25 0.25 0.39 0.18 0.16
Debt-to-Equity Ratio
 0.56 0.56 1.12 0.88 0.24
Debt-to-Capital Ratio
 0.36 0.36 0.53 0.47 0.20
Long-Term Debt-to-Capital Ratio
 0.20 0.20 0.40 0.33 0.15
Financial Leverage Ratio
 2.25 2.25 2.89 4.83 1.50
Debt Service Coverage Ratio
 -0.55 -1.73 0.29 -10.79 -6.57
Interest Coverage Ratio
 -8.05 -8.04 -2.25 -23.18 -13.51
Debt to Market Cap
 0.84 0.74 0.63 0.09 0.29
Interest Debt Per Share
 <0.01 <0.01 0.02 0.01 0.02
Net Debt to EBITDA
 -2.10 -0.65 1.18 -0.13 -0.06
Profitability Margins
Gross Profit Margin
75.07%36.19%67.99%23.08%0.00%
EBIT Margin
-322.53%-871.78%-0.51%-1218.13%0.00%
EBITDA Margin
-278.07%-827.46%13.54%-1189.29%0.00%
Operating Profit Margin
-874.73%-871.78%-70.52%-1035.29%0.00%
Pretax Profit Margin
-176.46%-171.69%-31.86%-1262.79%0.00%
Net Profit Margin
-101.65%-99.58%-31.86%-1262.79%0.00%
Continuous Operations Profit Margin
-175.01%-171.69%-31.86%-1262.79%0.00%
Net Income Per EBT
57.61%58.00%100.00%100.00%83.14%
EBT Per EBIT
20.17%19.69%45.18%121.97%85.57%
Return on Assets (ROA)
-2.94%-3.11%-23.70%-94.82%-27.16%
Return on Equity (ROE)
-6.12%-6.99%-68.50%-458.40%-40.80%
Return on Capital Employed (ROCE)
-35.98%-38.68%-86.84%-235.06%-44.38%
Return on Invested Capital (ROIC)
-30.91%-33.24%-71.60%-200.27%-35.82%
Return on Tangible Assets
-4.90%-5.18%-32.40%-123.52%-38.06%
Earnings Yield
-10.95%-10.27%-43.14%-58.19%-60.08%
Efficiency Ratios
Receivables Turnover
 2.60 2.80 7.49 6.78 0.00
Payables Turnover
 0.08 0.23 1.66 0.34 0.00
Inventory Turnover
 0.14 0.38 2.95 1.89 0.00
Fixed Asset Turnover
 1.38 1.49 21.39 2.54 0.00
Asset Turnover
 0.03 0.03 0.74 0.08 0.00
Working Capital Turnover Ratio
 0.09 0.11 3.60 0.21 0.00
Cash Conversion Cycle
 -1.52K -472.08 -47.35 -827.62 0.00
Days of Sales Outstanding
 140.60 130.33 48.72 53.84 0.00
Days of Inventory Outstanding
 2.66K 962.07 123.93 193.08 0.00
Days of Payables Outstanding
 4.32K 1.56K 219.99 1.07K 0.00
Operating Cycle
 2.80K 1.09K 172.65 246.92 0.00
Cash Flow Ratios
Operating Cash Flow Per Share
 >-0.01 >-0.01 -0.04 -0.02 -0.03
Free Cash Flow Per Share
 >-0.01 >-0.01 -0.04 -0.02 -0.03
CapEx Per Share
 <0.01 <0.01 <0.01 <0.01 <0.01
Free Cash Flow to Operating Cash Flow
 1.00 1.00 1.00 1.01 1.01
Dividend Paid and CapEx Coverage Ratio
 -304.36 -322.95 -812.46 -76.12 -83.04
Capital Expenditure Coverage Ratio
 -304.36 -322.95 -812.46 -76.12 -83.04
Operating Cash Flow Coverage Ratio
 -0.81 -0.86 -2.92 -1.95 -2.13
Operating Cash Flow to Sales Ratio
 -6.96 -6.84 -1.52 -4.71 0.00
Free Cash Flow Yield
-75.15%-70.82%-205.52%-21.99%-76.91%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 -9.11 -9.73 -2.32 -1.72 -1.66
Price-to-Sales (P/S) Ratio
 9.26 9.69 0.74 21.70 0.00
Price-to-Book (P/B) Ratio
 0.60 0.68 1.59 7.88 0.68
Price-to-Free Cash Flow (P/FCF) Ratio
 -1.33 -1.41 -0.49 -4.55 -1.30
Price-to-Operating Cash Flow Ratio
 -1.33 -1.42 -0.49 -4.61 -1.32
Price-to-Earnings Growth (PEG) Ratio
 -0.08 0.10 0.03 -0.01 0.05
Price-to-Fair Value
 0.60 0.68 1.59 7.88 0.68
Enterprise Value Multiple
 -5.43 -1.82 6.63 -1.95 -1.27
Enterprise Value
 17.90M 19.28M 25.98M 111.50M 36.27M
EV to EBITDA
 -5.44 -1.82 6.63 -1.95 -1.27
EV to Sales
 15.12 15.09 0.90 23.23 0.00
EV to Free Cash Flow
 -2.17 -2.20 -0.59 -4.87 -1.37
EV to Operating Cash Flow
 -2.17 -2.21 -0.59 -4.93 -1.38
Tangible Book Value Per Share
 <0.01 <0.01 <0.01 >-0.01 0.04
Shareholders’ Equity Per Share
 <0.01 <0.01 0.01 0.01 0.07
Tax and Other Ratios
Effective Tax Rate
 0.00 0.00 0.00 0.00 0.17
Revenue Per Share
 <0.01 <0.01 0.02 <0.01 0.00
Net Income Per Share
 >-0.01 >-0.01 >-0.01 -0.06 -0.03
Tax Burden
 0.58 0.58 1.00 1.00 0.83
Interest Burden
 0.55 0.20 62.73 1.04 0.86
Research & Development to Revenue
 6.88 6.44 0.32 2.61 0.00
SG&A to Revenue
 2.62 2.64 0.99 3.47 0.00
Stock-Based Compensation to Revenue
 0.29 0.00 0.04 0.48 0.00
Income Quality
 6.84 6.87 4.76 0.37 1.05
Currency in USD